Non-steroidal MRAs represent a novel class of agents showing promise in managing CKD by targeting the mineralocorticoid receptor (MR) without exhibiting the adverse effects of steroidal MRAs [30,31]. This evidence concerns the gene NR3C2 and chronic kidney disease.